MYNEO THERAPEUTICS

A little history

myNEO was founded in 2018 by leading biotech entrepreneurs combining expertise from different academic institutions. Cedric Bogaert, Jan Van Den Berghe, and Wim van Criekinge have since then expanded the team with established domain in antigen discovery experts as well as ambitious talent to further grow the company's innovation and developments.

myNEO offices

To date, myNEO has achieved several pivotal milestones in realizing its vision. These include:

  • Development of state-of-the-art antigen prediction algorithms
  • Discovery of novel, dark antigen targets called camyotopes
  • (Co-)development of novel immunotherapeutics products via strategic collaborations or in-house, leading to 3 separate programs executing successful IND/CTA filings in 2025
  • The publication of high-impact scientific papers
  • ISO and regulatory approval for clinical use of technology
  • Securing valuable intellectual property with multiple patents
  • Receiving several prestigious awards (Most Disruptive Innovator, Forbes 30under30, Rising Star Fast50)
Manon Montyne

Manon Montyne

Principal data scientist

Manon studied pharmaceutical sciences – drug development at Ghent University where she majored in personalized medicine. Passionate about both science and data analysis, she then obtained an additional master in bioinformatics – systems biology. She performed her thesis at the BIOBIX lab where she evaluated an allelic imbalance based regularized regression model to predict calendar age.

At myNEO, Manon's front-end and data visualization expertise drives all user-facing interface efforts across the platform portfolio, including myNEO (ImmunoEngine for personalized), mySURFACE, myADA, and myINSIGHTS. All custom-made visualization platforms that make complex datasets accessible and actionable are thanks to her work.

View LinkedIn profile